Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Atara Biotherap
(NQ:
ATRA
)
10.00
+0.95 (+10.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Atara Biotherap
< Previous
1
2
3
4
5
Next >
Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces $36 Million Registered Direct Offering
September 03, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
August 12, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 07, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
July 17, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
July 03, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
June 21, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
June 17, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
May 29, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
May 20, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
May 09, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
March 28, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
February 29, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
February 28, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
February 14, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
January 31, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
January 08, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
December 20, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
December 11, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
November 29, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference
November 22, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics To Participate at the Stifel Healthcare Conference
November 10, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.